Literature DB >> 20850917

Renal complications in transfusion-dependent beta thalassaemia.

Claudio Ponticelli1, Khaled M Musallam, Paolo Cianciulli, Maria Domenica Cappellini.   

Abstract

Increased survival in patients with β thalassaemia major (TM) allowed for several morbidities to manifest. Renal manifestations of the disease and its treatment have been poorly evaluated. There is evidence, mainly from studies in the paediatric population, of tubular dysfunction and glomerular filtration rate abnormalities in this patient population. Long-term outcomes of these changes, however, have not been prospectively investigated. The pathogenesis of these abnormalities could be attributed to iron overload, too aggressive iron removal, and/or the underlying anaemia. These changes seem to be nonprogressive, resolve spontaneously in most part, or may require iron chelator dose modifications. Relative iron depletion may explain renal function changes attributed to chelation therapy; thus, sudden removal of iron or overchelation should be avoided. Future studies should aim to evaluate the natural history of kidney function in TM patients to help understand the mechanisms and long-term sequelae of the observed renal changes.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20850917     DOI: 10.1016/j.blre.2010.08.004

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  22 in total

1.  Nocturnal enuresis in sickle cell disease and thalassemia major: associated factors in a clinical sample.

Authors:  Ozalp Ekinci; Tanju Celik; Şule Ünal; Gonul Oktay; Fevziye Toros; Cahit Ozer
Journal:  Int J Hematol       Date:  2013-09-08       Impact factor: 2.490

2.  Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures.

Authors:  P Wong; P J Fuller; M T Gillespie; V Kartsogiannis; B J Strauss; D Bowden; F Milat
Journal:  Osteoporos Int       Date:  2013-01-05       Impact factor: 4.507

Review 3.  Renal complications of beta-thalassemia major in children.

Authors:  Ashraf Bakr; Youssef Al-Tonbary; Ghada Osman; Rasha El-Ashry
Journal:  Am J Blood Res       Date:  2014-09-05

4.  Multidisciplinary evaluation at baseline and during treatment improves the rate of compliance and efficacy of deferasirox in elderly myelodysplastic patients.

Authors:  Lisette Del Corso; Lucia Biale; Emanuele Luigi Parodi; Rodolfo Russo; Rosa Filiberti; Eleonora Arboscello
Journal:  Int J Clin Oncol       Date:  2016-10-22       Impact factor: 3.402

5.  GFR in Patients with β-Thalassemia Major.

Authors:  Gai Milo; Revital Feige Gross Nevo; Idit Pazgal; Anat Gafter-Gvili; Ofer Shpilberg; Uzi Gafter; Arie Erman; Pinhas Stark
Journal:  Clin J Am Soc Nephrol       Date:  2015-05-11       Impact factor: 8.237

6.  Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review.

Authors:  Rebecca L C Adams; Robert J Bird
Journal:  Ther Adv Hematol       Date:  2013-04

Review 7.  Thalassemia-associated osteoporosis: a systematic review on treatment and brief overview of the disease.

Authors:  A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis
Journal:  Osteoporos Int       Date:  2016-08-08       Impact factor: 4.507

Review 8.  β-Thalassemia intermedia: a comprehensive overview and novel approaches.

Authors:  Chingiz Asadov; Zohra Alimirzoeva; Tahira Mammadova; Gunay Aliyeva; Shahla Gafarova; Jeyhun Mammadov
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

Review 9.  β-Thalassemia Intermedia: A Bird's-Eye View.

Authors:  Anthony Haddad; Paul Tyan; Amr Radwan; Naji Mallat; Ali Taher
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

10.  Comparing different markers of tubular dysfunction in transfusion-dependent thalassemia patients.

Authors:  Ilham Youssry; Samuel Makar; Khalil Abdelkhalek; Dina Hisham; Happy Sawires
Journal:  Int Urol Nephrol       Date:  2021-06-24       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.